The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
Open accessAbstract
Purpose: Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically important subtypes (ie, germinal center B-cell–like [GCB] and activated B-cell–like [ABC] DLBCL), which initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining. However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear. Patients and Methods: We studied 243 patient cases of de novo DLBCL, which included 131 patient cases treated with rituximab plus standard chemotherapy (rituximab group) and 112 patient cases treated with only standard chemotherapy (control group). The cases were assigned to GCB or non-GCB subgroups (the latter of which included both ABC DLBCL and unclassifiable DLBCL) on the basis of immunophenotype by using the Hans method. Clinical characteristics and survival outcomes of the two patient groups were compared. Results: The clinical characteristics of the patients in the rituximab and the control groups were similar. Compared with the control group, addition of rituximab improved the 3-year overall survival (OS; 42% v 77%; P < .001) of patients with DLBCL. Rituximab-treated patients in either the GCB or the non-GCB subgroups also had a significantly improved 3-year OS compared with their respective subgroups in the control group (P < .001). In the rituximab group, the GCB subgroup had a significantly better 3-year OS than the non-GCB subgroup (85% v 69%; P = .032). Multivariate analyses confirmed that rituximab treatment was predictive for survival in both the GCB and the non-GCB subgroups. Conclusion: In this retrospective study, we have shown that the subclassification of DLBCL on the basis of the cell of origin continues to have prognostic importance in the rituximab era.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationCoiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationHans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
Self-citationApplied Survival Analysis: Regression Modeling of Time-to-Event Data
Hosmer, D. W., Lemeshow, S. A., & May, S. J. (2008) · Cited by 3,030
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationDavis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Wright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 987
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 893
Anderson, J. R., Armitage, J. O., & Weisenburger, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008265532487 · Cited by 674
Self-citationMounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E., Tolcher, A. W., O'Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J. C., et al. (1997) · Blood · doi:10.1182/blood.v90.1.244 · Cited by 509
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
Kramer, M. H. H., Hermans, J., Wijburg, E., Philippo, K., Geelen, E., van Krieken, J. H. J. M., de Jong, D., Maartense, E., Schuuring, E., & Kluin, P. M. (1998) · Blood · doi:10.1182/blood.v92.9.3152 · Cited by 499
Hermine, O., Haioun, C., Lepage, E., d'Agay, M., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J., Diebold, J., et al. (1996) · Blood · doi:10.1182/blood.v87.1.265.265 · Cited by 452
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., & Kolch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389
Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., McFerran, B., Wyche, J., Kolch, W., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7207-7217.2001 · Cited by 387
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
Pasqualucci, L., Compagno, M., Houldsworth, J., Monti, S., Grunn, A., Nandula, S. V., Aster, J. C., Murty, V. V., Shipp, M. A., & Dalla-Favera, R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052204 · Cited by 370
Alas, S., & Bonavida, B. (2001) · PubMed · Cited by 331
Hill, M., MacLennan, K., Cunningham, D., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1046.1046 · Cited by 314
de Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., Sander, B., Thorns, C., Campo, E., Molina, T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4490 · Cited by 301
Iqbal, J., Neppalli, V. T., Wright, G., Dave, B. J., Horsman, D. E., Rosenwald, A., Lynch, J., Hans, C. P., Weisenburger, D. D., Greiner, T. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4264 · Cited by 298
Self-citationHuang, J. Z., Sanger, W. G., Greiner, T. C., Staudt, L. M., Weisenburger, D. D., Pickering, D. L., Lynch, J. C., Armitage, J. O., Warnke, R. A., Alizadeh, A. A., et al. (2002) · Blood · doi:10.1182/blood.v99.7.2285 · Cited by 290
Self-citation(2001) · PubMed · Cited by 279
Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A. P., Morgan, G. J., & Jack, A. S. (2002) · Blood · doi:10.1182/blood.v99.4.1136 · Cited by 276
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275
Harjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256
Lossos, I. S., Alizadeh, A. A., Eisen, M. B., Chan, W. C., Brown, P. O., Botstein, D., Staudt, L. M., & Levy, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316097 · Cited by 251
Self-citationMuris, J., Meijer, C., Vos, W., van Krieken, J., Jiwa, N., Ossenkoppele, G., & Oudejans, J. (2006) · The Journal of Pathology · doi:10.1002/path.1924 · Cited by 233
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas
Tam, W., Gomez, M., Chadburn, A., Lee, J. W., Chan, W. C., & Knowles, D. M. (2006) · Blood · doi:10.1182/blood-2005-09-3778 · Cited by 230
Self-citationWilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S., & Raffeld, M. (1997) · Blood · doi:10.1182/blood.v89.2.601 · Cited by 221
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91005-6 · Cited by 204
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time
Piris, M., Pezzella, F., Martinez-Montero, J., Orradre, J., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M., Martinez, B., Garrido, M., et al. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.61 · Cited by 185
Hassanzadeh Ghassabeh, G., De Baetselier, P., Brys, L., Noël, W., Van Ginderachter, J. A., Meerschaut, S., Beschin, A., Brombacher, F., & Raes, G. (2006) · Blood · doi:10.1182/blood-2005-04-1485 · Cited by 177
Flieger, D., Renoth, S., Beier, I., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1693 · Cited by 166
Vega, M. I., Huerta‐Yépez, S., Garbán, H., Jazirehi, A. R., Emmanouilides, C. E., & Bonavida, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207336 · Cited by 160
Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Ghetie, M.-A., Podar, E. M., Ilgen, A., Gordon, B. E., Uhr, J. W., & Vitetta, E. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7509 · Cited by 118
Funakoshi, S., Longo, D. L., & Murphy, W. J. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199603000-00002 · Cited by 41
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients
Lymphoma Study Division of the Korean Cancer Study Group, Park, Y. H., Lee, J. J., Ryu, M., Kim, S. Y., Kim, D. H., Do, Y. R., Lee, K. H., Oh, S. J., Kim, Y. K., et al. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0060-6 · Cited by 19
Cited by
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Self-citationGreen, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Choi, W. W. L., Weisenburger, D. D., Greiner, T. C., Piris, M. A., Banham, A. H., Delabie, J., Braziel, R. M., Geng, H., Iqbal, J., Lenz, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0113 · Cited by 642
Self-citationMartelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Metadata
- Authors
- Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K. D., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., Armitage, J. O., Chan, W. C., & Vose, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-01
- Volume
- 26
- Issue
- 28
- Pages
- 4587-4594
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096984838
- Cited by
- 334
- References
- 54
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.